National Public Health Leader Reed Tuckson, MD, Managing Director, Tuckson Health Connections, and Health Innovation Executive Vlad Coric, MD, CEO,…

By Dr. Matthew Watson

Award from Leading Life Science Forum Championing Sector Collaboration for Novel Solutions that Address Pressing Health Challenges is the Community’s Highest Honor

See the rest here:
National Public Health Leader Reed Tuckson, MD, Managing Director, Tuckson Health Connections, and Health Innovation Executive Vlad Coric, MD, CEO,...

Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024 - May 25th, 2024
Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications - May 25th, 2024
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid... - May 25th, 2024
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress - May 25th, 2024
Minutes of Annual General Meeting 2024 - May 25th, 2024
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit - May 25th, 2024
Monopar Announces CFO Succession - May 25th, 2024
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy - May 25th, 2024
Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company - May 25th, 2024
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 - May 25th, 2024
BioSenic provides First Quarter 2024 Business Update - May 25th, 2024
Purespring Therapeutics presents preclinical data at the 61st ERA Congress - May 25th, 2024
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress - May 25th, 2024
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome - May 25th, 2024
Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index - May 25th, 2024
Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet. - May 25th, 2024
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q - May 25th, 2024
Iovance Biotherapeutics to Present at Upcoming Conferences and Events - May 25th, 2024
Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - May 25th, 2024
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting - May 25th, 2024
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy... - May 17th, 2024
Thrive Bioscience Welcomes Todd Lewis as Chief Commercial Officer - May 17th, 2024
Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024 - May 17th, 2024
Assertio to Participate in AGP Healthcare Conference on May 21 - May 17th, 2024
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH - May 17th, 2024
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives - May 17th, 2024
Digital Utilities Ventures Completes Feed Earth Now Merger - Accelerates Growth of Regenerative Agriculture Movement - May 17th, 2024
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 - May 17th, 2024
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - May 17th, 2024
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference - May 17th, 2024
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with... - May 17th, 2024
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference - May 17th, 2024
BioSyent Releases Financial Results for Q1 2024 - May 17th, 2024
BioSyent Declares Second Quarter 2024 Dividend - May 17th, 2024
Lifecore Biomedical Completes Incremental Liquidity Initiatives - May 17th, 2024
DBV Technologies Announces Results of its 2024 Combined General Meeting - May 17th, 2024
Fortrea Appoints Machelle Sanders to Board of Directors - May 17th, 2024
QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency - May 17th, 2024
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise - May 17th, 2024
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress - May 17th, 2024
Telesis Bio Announces Reverse Stock Split - May 7th, 2024
Shockwave Medical Reports First Quarter 2024 Financial Results - May 7th, 2024
Aileron Therapeutics to Present at Two Upcoming Investor Conferences - May 7th, 2024
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates - May 7th, 2024
Sana Biotechnology to Present at May and June 2024 Investor Conferences - May 7th, 2024
Day One Reports First Quarter 2024 Financial Results and Corporate Progress - May 7th, 2024
Immuneering Recognizes Melanoma Awareness Month - May 7th, 2024
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity - May 7th, 2024
Helio Genomics to Showcase Results from CLiMB Pivotal Trial in an Oral Presentation at the EASL Congress 2024 - May 7th, 2024
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor - May 7th, 2024
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 - May 7th, 2024
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million - May 7th, 2024
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7th, 2024
T2 Biosystems Announces First Quarter 2024 Financial Results - May 7th, 2024
argenx to Present at BofA Securities 2024 Health Care Conference - May 7th, 2024
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update - May 7th, 2024
Sandoz reports first quarter 2024 sales - May 7th, 2024
Memo Therapeutics increases Series C financing to CHF 45 million - May 7th, 2024
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025 - May 7th, 2024
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 7th, 2024
Medigene AG reports Financial Results and Business Update for Q1 2024 - April 28th, 2024
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 - April 28th, 2024
Composition of the Nomination Committee of Orion Corporation - April 28th, 2024
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) - April 28th, 2024
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - April 28th, 2024
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - April 28th, 2024
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal... - April 28th, 2024
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) - April 28th, 2024
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - April 28th, 2024
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management - April 28th, 2024
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - April 28th, 2024
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments - April 28th, 2024
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners - April 28th, 2024
BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles - April 28th, 2024
Sino Biological Finalizes the Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio - April 28th, 2024
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update - April 28th, 2024
Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders - April 28th, 2024
Financière de Tubize - Dividend approval - April 28th, 2024

Global News Feed commento

Comments Off | data

November 22nd, 2022

About... Dr. Matthew Watson

This author published 5552 posts in this site.

Comments are closed.

Previous post - Next post

National Public Health Leader Reed Tuckson, MD, Managing Director, Tuckson Health Connections, and Health Innovation Executive Vlad Coric, MD, CEO,…

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites